A biotechnology firm is growing at a compound rate of more than 21 percent a year. (Its

Question:

A biotechnology firm is growing at a compound rate of more than 21 percent a year. (Its ROE is over 30 percent, and it retains about 70 percent of its earnings.) The stock of this company is priced at about 65 times next year's earnings. Discuss whether you consider this a growth company and/or a growth stock.